Holly Springs, N.C.— Genentech, a member of the Roche Group, has announced plans to invest over $700 million in a new 700,000-square-foot drug manufacturing facility in Holly Springs, marking the company’s first manufacturing site on the East Coast. The project is expected to create more than 400 high-wage jobs once operational, along with 1,500 construction jobs during development.
The state-of-the-art facility will support Roche and Genentech’s growing portfolio of metabolic and next-generation obesity medicines. The investment reflects the company’s long-term commitment to strengthening its U.S. manufacturing network, with the potential for future expansion depending on business demands and the broader policy environment.
“Our new facility near Raleigh, North Carolina, an established biopharmaceutical talent hub, will serve as an important new setting within our manufacturing network to help deliver on the promise of our company’s life-changing science and industry-leading pipeline,” said Genentech CEO Ashley Magargee. “We are thrilled to establish this relationship with the city of Holly Springs, where we expect to have a positive impact on the local economy and community.”
North Carolina Governor Josh Stein welcomed the announcement, highlighting the state’s growing status as a hub for life sciences and biotech manufacturing. “I’m proud that Genentech has chosen North Carolina for its first facility on the East Coast,” said Stein. “This major investment in Holly Springs shows that our state continues to be a leading destination for life sciences and advanced manufacturing.”
Genentech and Roche currently operate 13 manufacturing and 15 research and development sites in the U.S., employing over 25,000 people across 24 facilities in eight states. The company’s latest expansion underscores its commitment to building the infrastructure, talent base, and innovation capacity necessary to accelerate the development and production of new therapies.
The Holly Springs project positions Genentech as a major new player in North Carolina’s rapidly expanding biotechnology sector, which has seen increasing investment from global pharmaceutical and life sciences companies in recent years.
